The disagreement stemmed from differing interpretations of value addition caps post-GST implementation. The CBIC’s clarification resolves concerns, particularly for pharmaceutical units, and should apply across industries claiming refunds.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Leave a Comment